Tango Therapeutics' Stock Sinks To US$2.62, But Insiders Sold Even Lower

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) stock price has dropped 19% in the previous week, but insiders who sold US$302k in stock over the past year have had less luck. Insiders would probably have been better off holding on to their shares given that the average selling price of US$12.59 is still lower than the current share price.

While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.

Check out our latest analysis for Tango Therapeutics

Tango Therapeutics Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider sale was by the President, Barbara Weber, for US$115k worth of shares, at about US$12.62 per share. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The silver lining is that this sell-down took place above the latest price (US$2.62). So it may not tell us anything about how insiders feel about the current share price.

All up, insiders sold more shares in Tango Therapeutics than they bought, over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).

Tango Therapeutics Insiders Bought Stock Recently

Over the last three months, we've seen significant insider buying at Tango Therapeutics. Independent Director Mace Rothenberg spent US$74k on stock, and there wasn't any selling. This makes one think the business has some good points.

Insider Ownership Of Tango Therapeutics

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. From our data, it seems that Tango Therapeutics insiders own 1.8% of the company, worth about US$5.0m. We do generally prefer see higher levels of insider ownership.

What Might The Insider Transactions At Tango Therapeutics Tell Us?

The recent insider purchase is heartening. On the other hand the transaction history, over the last year, isn't so positive. The transactions over the last year don't give us confidence, and nor does the fairly low insider ownership, but at least the recent buying is a positive. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. You'd be interested to know, that we found 3 warning signs for Tango Therapeutics and we suggest you have a look.

Of course Tango Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.